News Channels

25 May 2018 Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer
25 May 2018 SOTIO Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy
25 May 2018 Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients
25 May 2018 Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca
25 May 2018 BioMarin Receives Standard Approval for Palynziq™ (pegvaliase-pqpz) Injection for Treatment of Adults with Phenylketonuria (PKU), a Rare Genetic Disease
25 May 2018 Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
25 May 2018 Enrolment Completed in Cynata’s Phase 1 Clinical Trial of CYP-001 in GvHD
25 May 2018 ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
25 May 2018 Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
25 May 2018 BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
24 May 2018 Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin's Lymphoma
24 May 2018 San Diego-based Epigen Biosciences enters a collaboration to license its LPA1 Receptor small molecule program to Novo Nordisk A/S for up to USD 200 Million
24 May 2018 IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
24 May 2018 Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
23 May 2018 FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
23 May 2018 FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy
23 May 2018 FDA Accepts Supplemental Biologics License Application (BLA) and Grants Priority Review for Prophylactic and Pediatric Use for Bio Products Laboratory's Coagadex® (Coagulation Factor X, Human) for Treatment of Hereditary Factor X Deficiency
23 May 2018 mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
23 May 2018 Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
23 May 2018 Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up